NEW YORK, NY / ACCESS Newswire / August 10, 2025 / If you suffered a loss on your Centene Corporation (NYSE:CNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/centene-corporation-lawsuit-submission-form?prid=160701&wire=1&utm_campaign=23 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call […]

Washington, D.C., Aug. 10, 2025 (GLOBE NEWSWIRE) — Former CIA advisor and economic strategist Jim Rickards highlights in a briefing what he calls a “generational opening”–a rare window where younger Americans may have access to something their parents and grandparents lost long ago: a tangible path to wealth. “You don't need a trust fund or

The Window to Build Real Wealth May Be Reopening–And This Presentation Shows Where to Look GlobeNewswire August 10, 2025 Washington, D.C., Aug. 10, 2025 (GLOBE NEWSWIRE) — Former CIA advisor and economic strategist Jim Rickards highlights in a briefing what he calls a “generational opening”–a rare window where younger Americans may have access to something

NEW YORK, NY / ACCESS Newswire / August 10, 2025 / If you suffered a loss on your Sarepta Therapeutics, Inc. (NASDAQ:SRPT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sarepta-lawsuit-submission-form?prid=160699&wire=1&utm_campaign=14 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / August 10, 2025 / If you suffered a loss on your Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/rocket-pharmaceuticals-inc-lawsuit-submission-form?prid=160698&wire=1&utm_campaign=9 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / August 10, 2025 / If you suffered a loss on your Replimune Group, Inc. (NASDAQ:REPL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/replimune-group-inc-lawsuit-submission-form?prid=160700&wire=1&utm_campaign=11 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Altimmune, Inc. (“Altimmune” or “the Company”) (NASDAQ: ALT) and certain of its officers. https://mma.prnewswire.com/media/439152/Bronstein_Gewirtz_and_Grossman_LLC_logo.jpg Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities

(NasdaqGM:RDNT), Total Company Revenue increased 8.4% to a quarterly record of $498.2 million in the second quarter of 2025 from $459.7 million in the second quarter of 2024; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 30.9% to a quarterly record of $20.7 million in the second quarter of 2025 from

(NasdaqGM:RCKT), NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (“Rocket” or “the Company”) (NASDAQ: RCKT) and certain of its officers. Class Definition This lawsuit seeks to recover damages

(NASDAQ:AAPL), NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Apple Inc. (“Apple” or “the Company”) (NASDAQ: AAPL) and certain of its officers. Class Definition This lawsuit seeks to recover damages against